Ionis Pharmaceuticals Inc... (IONS)
Ionis Pharmaceuticals Inc. (IONS) Stock Price, Analysis & Data
| Bid | 51.83 |
| Market Cap | 9.4B |
| Revenue (ttm) | 874.09M |
| Net Income (ttm) | -565.17M |
| Beta | 0.40 |
| EPS (ttm) | -3.48 |
| PE Ratio (ttm) | n/a |
| Forward PE | -48.78 |
| P/B (ttm) | 21.31 |
| P/S (ttm) | 10.76 |
| Earnings Date | Nov 4, 2026 |
| Ask | 60.54 |
| Volume | 1,018,632 |
| Avg. Volume (20D) | 2,868,388 |
| Open | 55.83 |
| Previous Close | 55.42 |
| Day's Range | 54.92 - 57.06 |
| 52-Week Range | 41.54 - 86.74 |
| Analyst | Buy |
| Price Target | 90 (59.04%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) i...
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was 943.71M, an increase of 33.83% compared to the previous year's 705.14M. Earnings were -381.39M, a decrease of -15.97%.
Financial StatementsAnalyst Forecast
According to 21 analyst ratings, the average rating for IONS stock is "Buy". The 12-month stock price forecast is 90, which is upside of 59.04% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
